- Home
- OPRX vs CHRS Comparison
OPRX vs CHRS Comparison
Compare OPRX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- CHRS
- Stock Information
- Founded
- OPRX 2006
- CHRS 2010
- Country
- OPRX United States
- CHRS United States
- Employees
- OPRX N/A
- CHRS 235
- Industry
- OPRX Business Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPRX Consumer Discretionary
- CHRS Health Care
- Exchange
- OPRX Nasdaq
- CHRS Nasdaq
- Market Cap
- OPRX 137.6M
- CHRS 96.9M
- IPO Year
- OPRX N/A
- CHRS 2014
- Fundamental
- Price
- OPRX $8.16
- CHRS $0.95
- Analyst Decision
- OPRX Buy
- CHRS Strong Buy
- Analyst Count
- OPRX 8
- CHRS 4
- Target Price
- OPRX $9.06
- CHRS $5.38
- AVG Volume (30 Days)
- OPRX 360.9K
- CHRS 1.9M
- Earning Date
- OPRX 05-13-2025
- CHRS 05-08-2025
- Dividend Yield
- OPRX N/A
- CHRS N/A
- EPS Growth
- OPRX N/A
- CHRS N/A
- EPS
- OPRX N/A
- CHRS 0.25
- Revenue
- OPRX $92,127,000.00
- CHRS $266,959,999.00
- Revenue This Year
- OPRX $12.12
- CHRS N/A
- Revenue Next Year
- OPRX $10.87
- CHRS $9.02
- P/E Ratio
- OPRX N/A
- CHRS $3.36
- Revenue Growth
- OPRX 28.81
- CHRS 3.78
- 52 Week Low
- OPRX $3.78
- CHRS $0.66
- 52 Week High
- OPRX $14.13
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- OPRX 54.72
- CHRS 50.20
- Support Level
- OPRX $6.80
- CHRS $0.72
- Resistance Level
- OPRX $8.34
- CHRS $0.90
- Average True Range (ATR)
- OPRX 0.75
- CHRS 0.09
- MACD
- OPRX -0.14
- CHRS 0.01
- Stochastic Oscillator
- OPRX 49.23
- CHRS 71.10
Stock Price Comparison Chart: OPRX vs CHRS
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.